NCT03359499View on ClinicalTrials.gov

Impact of Bacillus Clausii Administration on Irritable Bowel Syndrome Patients

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

August 12, 2017

Primary Completion Date

October 25, 2017

Study Completion Date

November 23, 2017

Conditions
Irritable Bowel Syndrome
Interventions
DRUG

Bacillus clausii

Oral suspension administered BID

DRUG

Trimebutine

One tablet of 200 mg of trimebutine administered BID

Trial Locations (1)

1012

Hospital Britanico, Buenos Aires

All Listed Sponsors
lead

Hospital Britanico

OTHER

NCT03359499 - Impact of Bacillus Clausii Administration on Irritable Bowel Syndrome Patients | Biotech Hunter | Biotech Hunter